Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9

Chong, Gun Oh; Jeon, Hyo-Sung; Han, Hyung Soo; Son, Ji Woong; Lee, Yoon Hee; Hong, Dae Gy; Park, Hong Jun; Cho, Young Lae

doi:10.21873/cgp.20026

Cited by 22 publications

(12 citation statements)

References 27 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study reported that overexpression of miR-196b may contribute to invasion activities of cancer cells in recurrent epithelial ovarian cancer by regulating the Homeobox A9 gene. 23 The methylation status of the miR-196b promoter region affects the level of miR-196b expression in tumors. In the study of gastric cancer, oral cancer, and melanoma, hypomethylation of the miR-196b promoter region increased the expression of miR-196b.…”

Section: Discussionmentioning

confidence: 99%

<p>High Expression of miR-196b Predicts Poor Prognosis in Patients with Ovarian Cancer</p>

Li¹,

Li²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

Background/Aims: To analyze the clinical significance of miR-196b expression in ovarian cancer and predict the function and possible mechanism of miR-196b. Methods: Both Kaplan-Meier (K-M) and Cox proportional hazards regression model were used to analyze the prognostic factors of patients with ovarian cancer. MiR196-b was modulated in ovarian cancer cells, and the cell viability, cell cycle, and cell cycle-related gene expression were analyzed. The target genes of miR-196b were then predicted and checked the relationship between the target genes. Results: MiR-196b was an independent risk factor, while high expression of miR-196b was associated with poor prognosis of ovarian cancer. MiR-196b overexpression increased cancer cell proliferation. Cdkn1b, as one of the targets of miR-196b, was related to cell viability and mitosis. Conclusion: High expression of miR-196b was significantly associated with poor prognosis of the patients with ovarian cancer. MiR-196b could increase the cell proliferation of ovarian cancer by modulating Cdkn1b expression.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>High Expression of miR-196b Predicts Poor Prognosis in Patients with Ovarian Cancer</p>

Li¹,

Li²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…Multiple studies indicate that hsa-mir196-b overexpression is bad for the cancer patient. For example, hsa-mir196-b overexpression is associated with poor prognosis in gastric cancer (Lim et al, 2013; Ge et al, 2014), and is also associated with accelerated invasiveness in epithelial ovarian cancer (Chong et al, 2017). Kanno et al, (2017) reported that hsa-mir-196b overexpression might be a prognostic biomarker for a bad outcome.…”

Section: Discussionmentioning

confidence: 99%

Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma

2019

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is the most common and among the deadliest of pancreatic cancers. Its 5-year survival is only ∼8%. Pancreatic cancers are a heterogeneous group of diseases, of which PDAC is particularly aggressive. Like many other cancers, PDAC also starts as a pre-invasive precursor lesion (known as pancreatic intraepithelial neoplasia, PanIN), which offers an opportunity for both early detection and early treatment. Even advanced PDAC can benefit from prognostic biomarkers. However, reliable biomarkers for early diagnosis or those for prognosis of therapy remain an unfulfilled goal for PDAC. In this study, we selected 153 PDAC patients from the TCGA database and used their clinical, DNA methylation, gene expression, and micro-RNA (miRNA) and long non-coding RNA (lncRNA) expression data for multi-omics analysis. Differential methylations at about 12,000 CpG sites were observed in PDAC tumor genomes, with about 61% of them hypermethylated, predominantly in the promoter regions and in CpG-islands. We correlated promoter methylation and gene expression for mRNAs and identified 17 genes that were previously recognized as PDAC biomarkers. Similarly, several genes (B3GNT3, DMBT1, DEPDC1B) and lncRNAs (PVT1, and GATA6-AS) are strongly correlated with survival, which have not been reported in PDAC before. Other genes such as EFR3B, whose biological roles are not well known in mammals are also found to strongly associated with survival. We further identified 406 promoter methylation target loci associated with patients survival, including known esophageal squamous cell carcinoma biomarkers, cg03234186 (ZNF154), and cg02587316, cg18630667, and cg05020604 (ZNF382). Overall, this is one of the first studies that identified survival associated genes using multi-omics data from PDAC patients.

show abstract

“…HOXA9 is a member of the HOX gene family reported to have crucial roles in regulating hematopoiesis ( 37 ). Previous studies have shown that HOXA9 was the target of miRNAs in acute myeloid leukemia ( 38 ), in cutaneous squamous cell carcinoma ( 39 ) and in ovarian cancer ( 40 ). Therefore, we investigated whether HOXA9 was a mediator of miR-429 tumor inhibition in OS cells.…”

Section: Discussionmentioning

confidence: 99%

miR‑429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β‑catenin signaling pathway

Sun

Wang²,

Luan

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most commonly diagnosed malignant cancer of bone that occurs in adolescents and children. Mounting number of studies have indicated that miRNAs are increasingly playing fundamental roles in OS development. Thus, the biological function of miR-429 in OS progression was explored. The results of RT-qPCR revealed that miR-429 was downregulated in OS tissues and OS cell lines (MG-63, U2OS, Saos-2) while homeobox A9 (HOXA9) was markedly increased. Moreover, HOXA9 was confirmed as a direct target of miR-429 by using luciferase reporter assay. It was identified that miR-429 exhibited a suppressive effect on OS progression while HOXA9 showed the oncogenic function in OS progression by using MTT and Transwell assays. More importantly, rescue assays manifested that HOXA9 can partially overturn the suppressive effect of miR-429 on OS. Overexpression of miR-429 inhibited the activation of Wnt/β-catenin signaling pathway. In conclusion, miR-429 suppressed OS progression by targeting HOXA9 through Wnt/β-catenin pathway.

show abstract

Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9

Abstract: Abstract. Background

Cited by 22 publications

References 27 publications

<p>High Expression of miR-196b Predicts Poor Prognosis in Patients with Ovarian Cancer</p>

<p>High Expression of miR-196b Predicts Poor Prognosis in Patients with Ovarian Cancer</p>

Survival Analysis of Multi-Omics Data Identifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma

miR‑429 inhibits osteosarcoma progression by targeting HOXA9 through suppressing Wnt/β‑catenin signaling pathway

Contact Info

Product

Resources

About